Overview

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral HRS5685 in Healthy Subjects

Status:
Not yet recruiting
Trial end date:
2023-03-10
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blinded, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single ascending dose (Part A) and multiple ascending dose (Part B) of HRS5685 tablet in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
RetroLead (Shanghai) BioPharma Co., Ltd.